Surgical Endoscopy

, Volume 23, Issue 12, pp 2855–2857 | Cite as

Preventing and managing complications of laparoscopic gastrectomy

Letter

References

  1. 1.
    Kim W, Song KY, Lee HJ, Han SU, Hyung WJ, Cho GS (2008) The impact of co morbidity on surgical outcomes in laparoscopy-assisted distal gastrectomy: a retrospective analysis of multicenter results. Ann Surg 248(5):793–799CrossRefPubMedGoogle Scholar
  2. 2.
    Sasako M, Sano T, Yamamoto S et al for Japan Clinical Oncology Group (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359(5):453–462Google Scholar
  3. 3.
    Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62CrossRefPubMedGoogle Scholar
  4. 4.
    Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727–730CrossRefPubMedGoogle Scholar
  5. 5.
    Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24PubMedGoogle Scholar
  6. 6.
    Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255CrossRefPubMedGoogle Scholar
  7. 7.
    Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas-Couchell S (1990) A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. J Cancer Res Clin Oncol 116:307–311CrossRefPubMedGoogle Scholar
  8. 8.
    Gilbert SM, Hollenbeck BK (2009) Limitations of lymph node counts as a measure of therapy. J Natl Compr Cancer Netw 7(1):58–61Google Scholar
  9. 9.
    Bo T, Zhihong P, Peiwu Y et al (2009) General complications following laparoscopic-assisted gastrectomy and analysis of techniques to manage them. Surg Endosc, 30 Jan 2009. [Epub ahead of print]Google Scholar
  10. 10.
    Wong SL, Ji H, Hollenbeck BK, Morris AM, Baser O, Birkmeyer JD (2007) Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 298(18):2149–2154CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726 CrossRefPubMedGoogle Scholar
  12. 12.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMedGoogle Scholar
  13. 13.
    Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602–1609CrossRefPubMedGoogle Scholar
  14. 14.
    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMedGoogle Scholar
  16. 16.
    Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMedGoogle Scholar
  17. 17.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129CrossRefPubMedGoogle Scholar
  20. 20.
    Liakakos T, Roukos DH (2008) More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960CrossRefPubMedGoogle Scholar
  21. 21.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMedGoogle Scholar
  22. 22.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715CrossRefPubMedGoogle Scholar
  23. 23.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33CrossRefPubMedGoogle Scholar
  24. 24.
    Agnantis NJ, Paraskevaidis E, Roukos DH (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034CrossRefPubMedGoogle Scholar
  25. 25.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361CrossRefPubMedGoogle Scholar
  27. 27.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636Google Scholar
  29. 29.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMedGoogle Scholar
  30. 30.
    Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMedGoogle Scholar
  32. 32.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalizd breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMedGoogle Scholar
  33. 33.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMedGoogle Scholar
  34. 34.
    Roukos DH (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMedGoogle Scholar
  35. 35.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMedGoogle Scholar
  36. 36.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMedGoogle Scholar
  37. 37.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362–1363CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Akademisches Lehrkrankenhaus der JWG-Universitat, Klinik fur Allgemein-, Viszeral-, und Endokrine Chirurgie, Asklepios Klinik LangenLangenGermany

Personalised recommendations